According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, William Blair reaffirmed a market perform rating on shares of Sientra in a report on Wednesday, August 10th.
Shares of Sientra (NASDAQ:SIEN) opened at 8.83 on Wednesday. The firm has a 50-day moving average price of $8.53 and a 200-day moving average price of $7.44. The stock’s market cap is $160.12 million. Sientra has a 12 month low of $2.78 and a 12 month high of $10.45.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.05. Sientra had a negative net margin of 297.09% and a negative return on equity of 36.16%. The company earned $6.20 million during the quarter, compared to analysts’ expectations of $4.80 million. Equities analysts expect that Sientra will post ($2.31) EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in SIEN. First New York Securities LLC NY raised its stake in Sientra by 411.4% in the second quarter. First New York Securities LLC NY now owns 15,343 shares of the company’s stock valued at $101,000 after buying an additional 12,343 shares in the last quarter. State Street Corp raised its stake in Sientra by 23.9% in the first quarter. State Street Corp now owns 82,717 shares of the company’s stock valued at $563,000 after buying an additional 15,954 shares in the last quarter. Geode Capital Management LLC raised its stake in Sientra by 67.5% in the first quarter. Geode Capital Management LLC now owns 71,919 shares of the company’s stock valued at $491,000 after buying an additional 28,980 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Sientra during the second quarter valued at approximately $198,000. Finally, Cannell Capital LLC raised its stake in Sientra by 95.2% in the second quarter. Cannell Capital LLC now owns 855,997 shares of the company’s stock valued at $5,632,000 after buying an additional 417,364 shares in the last quarter. Institutional investors and hedge funds own 68.85% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.